Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
IDWeek, the combined annual meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and…
From - Diagnostic Testing & Emerging Technologies
PAMA implementation is so sweeping that it requires a shift in not just payment paradigm but also CPT codes. This has served as the impetus for…
By Mike O'Brien bio
Your news feed, like mine, has exploded with references to someone named Harvey Weinstein for the past few weeks. What's up? Weinstein is…
From - Diagnostic Testing & Emerging Technologies
In a case to watch, CareFirst BlueCross BlueShield will ask the U.S. Supreme Court to consider its first health care data breach case. CareFirst is arguing that the…
From - Diagnostic Testing & Emerging Technologies
A recurring theme at G2's 35th annual Lab Institute conference (Washington D.C.; Oct. 25-27) was the central role laboratory data can play…